Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chromosome 17 deletion × daratumumab × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 117 Recurrence 9 Immunoglobulin Light-chain Amyloidosis 6 Neoplasms, Plasma Cell 5 Neoplasms 5 Lymphoma, Non-Hodgkin 5 Leukemia, Myeloid, Acute 4 Smoldering Multiple Myeloma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Neoplasm, Residual 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Hodgkin Disease 3 Hematologic Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Plasmacytoma 2 Acute Kidney Injury 2 Triple Negative Breast Neoplasms 1 Proteostasis Deficiencies 1 Primary Myelofibrosis 1 Plasmablastic Lymphoma 1 Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Microsatellite Unstable Colorectal Cancer 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1

Interventions

pomalidomide 2 fludarabine phosphate 2 Dexamethasone 2 venetoclax 1 pembrolizumab 1 ibrutinib 1 fludarabine 1 daratumumab 1 acalabrutinib 1 Tacrolimus 1 Sirolimus 1 Peripheral Blood Stem Cell Transplantation 1 Melphalan 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04124497 2025-08-08

DPd

Fondazione EMN Italy Onlus

Phase 2 Active not recruiting

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡